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Free radicals, particularly reactive oxygen species (ROS), are involved in various pathologies, injuries
related to radiation, ischemia-reperfusion or ageing. Unfortunately, it is virtually impossible to directly
detect free radicals in vivo, but the redox status of the whole organism or particular organ can be studied
in vivo by using magnetic resonance techniques (EPR and MRI) and paramagnetic stable free radicals –
nitroxides. Here we review results obtained in vivo following the pharmacokinetics of nitroxides on
experimental animals (and a few in humans) under various conditions. The focus was on conditions
where the redox status has been altered by induced diseases or harmful agents, clearly demonstrating
that various EPR/MRI/nitroxide combinations can reliably detect metabolically induced changes in the
redox status of organs. These ﬁndings can improve our understanding of oxidative stress and provide a
basis for studying the effectiveness of interventions aimed to modulate oxidative stress. Also, we an-
ticipate that the in vivo EPR/MRI approach in studying the redox status can play a vital role in the clinical
management of various pathologies in the years to come providing the development of adequate
equipment and probes.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Reactive oxygen species (ROS) are generated constantly in liv-
ing cells. Their overall effect on cells and tissues is determined by
the rate of their production and the concentration of low-mole-
cular-weight antioxidants and activity of enzymatic antioxidants
which is often described as the redox state or bioreductive capa-
city of the system (buffer capacity) [1]. Numerous factors can in-
ﬂuence the redox state, either by decreasing antioxidant capacity
(redox buffer capacity) or increasing the rate of ROS production,
both leading to the enhanced oxidative damage of cells and tis-
sues. Oxidative stress has been implicated in a number of patho-
logical conditions such as ischemia, diabetes, neurological dis-
orders, but it can also be a consequence of external factors such as
irradiation, intoxication, use of prescribed and other drugs, etc. [2].
It is no surprise, therefore, that numerous studies have been
performed while studying ROS in trying to understand the un-
derlying mechanisms with the ultimate goal of preventing or
minimizing their deleterious action. Studies of indirect ROS de-
tection range from assessment of the oxidative products (DNA/
RNA damage, lipid peroxidation) through measurements of theB.V. This is an open access article uantioxidant defense system (SOD, glutathione, etc.) to behavioral
studies. An ideal technique should be able to directly and non-
invasively measure ROS in vivo. Spectroscopic techniques that can
measure free radicals using probes or directly have been reviewed
[3]. Techniques such as ﬂuorescence and luminescence are widely
used for studying cells and tissues in vitro, but are hardly applic-
able for in vivo studies due to the low penetration depth of used
light. Electron paramagnetic resonance (EPR) has advantages since
it can, in principle, detect ROS directly and the used electro-
magnetic waves have sufﬁcient penetration depth for in vivo stu-
dies, but the situation is not that ideal in real circumstances.
Zavoyski [4] discovered EPR (also called electron spin resonance,
ESR) in 1946, almost at the same time when nuclear magnetic re-
sonance (NMR) was discovered. Both techniques were intended as a
tool for investigation in solid state physics, but they soon were em-
ployed in studying biological/biochemical systems. The early studies
were inﬂuenced by the low sensitivity of available EPR spectrometers
and difﬁculties in overcoming the problem of non-resonant absorp-
tion of microwaves by watery samples. Nevertheless, efforts to study
cells and tissues by EPR continued, mostly motivated by the spec-
ulations that enzymatic reactions involve the creation of free radicals
and that free radicals might be involved in the development of
cancer, so that by 1970s EPR became a well-established and re-
spectable technique in the ﬁeld of biological/biochemical research.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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opment of the loop-gap resonator in 1982 [5] turned out to be a
major breakthrough for in vivo EPR. This was soon accompanied by
the development of a resonant cavity resonator suitable for whole
body experiments on mice [6]. Application of EPR to in vivo biological
systems essentially started as development of EPR imaging (EPRI)
[7,8]. In parallel, extensive work on models and in vitro samples has
been conducted in establishing basic principles of imaging techni-
ques, contrast enhancement and image reconstruction [9–13]. All this
work has been performed by adding external paramagnetic agents,
nitroxides (see Section 3), since biological systems do not produce
sufﬁcient amounts of radicals to be detected in vivo. Next, the ﬁrst
in vivo pharmacokinetic experiment has been performed using EPR
spectroscopy (EPRS), where injected nitroxides were used to probe
redox processes [14]. All these experiments stimulated development
of different EPR machines suitable for in vivo experiments, and which
is equally important, synthesis of new nitroxides that can fulﬁl spe-
ciﬁc needs for in vivo experiments [15–22]. These articles have been
mostly aimed at demonstrating that it is feasible to study the phar-
macokinetics of nitroxides, but soon these were followed by studies
where the inﬂuence of different pathologies on the redox status were
investigated (see Section 5). Since the early 90s the ﬁeld of in vivo
EPR has grown tremendously in the next two decades to the extent
that a complete volume of Biological Magnetic Resonance was nee-
ded to cover all the advances and techniques [23]. Much of this work
has been stimulated by the discovery that the rate of reduction of
nitroxides in cells and tissues is highly dependent on the con-
centration of oxygen (see e.g. [24,25]).
The realization that one can introduce metabolically responsive
and relatively stable paramagnetic free radicals in the body
prompted the introduction of another resonance technique
(magnetic resonance imaging, MRI) in the ﬁeld of redox research.
At the beginning, nitroxides were studied as potential clinical
contrast agents, primarily for tumors [26]. However, relaxation
enhancement of nitroxides and corresponding contrast on MR
images is around 10 times lower than with a standard MRI con-
trast agent (Gd-DTPA) per unit of concentration, so little further
effort has been put along that line of research. However, with the
advent of MRI machines for small animals numerous researches
have been recently devoted to studying the redox state under
different pathological conditions using nitroxides [27–31].
The main scope of this review is to cover research where the
pharmacokinetics of nitroxides has been studied with a goal to in-
vestigate redox processes in normal and pathological conditions. The
emphasis is on results obtained using EPR techniques, but examples
from MRI studies are given when the focus of the study is on the
pharmacokinetics of nitroxides and not just imaging using nitroxides
as contrast agents. Particular attention is given to how fruitful a
combination of EPR and MRI can be in achieving optimal analysis of
the investigated subject. Details on EPR imaging alone of the oxida-
tive stress can be found in the recent review [32]. Perhaps the most
powerful application of in vivo EPRI is measurement of oxygen (EPR
oximetry), but this subject will not be covered per se in this review.
EPR oximetry has been extensively and regularly reviewed [33–35]
and oximetry will be considered only when directly connected with
the pharmacokinetics of nitroxides. The purpose of this review is not
only to summarize results obtained so far but also to point to certain
ﬂaws in conducted research and to indicate a possible direction for
improvement and development.2. Technical consideration of magnetic resonance spectro-
scopy/imaging in vivo
Both EPR and NMR are resonant techniques that record spin
transitions when a system in the magnetic ﬁeld is exposed toadequate (resonant) electromagnetic irradiation. Although there
are few fundamental differences between the principles of elec-
tron and nuclear magnetic resonance, differences in physical
properties of the resonant species (unpaired electrons vs. nuclei
with net spin) lead to profound differences in applications and
techniques that are used to record spectra. Perhaps the greatest
differences arise because the gyromagnetic ratio of an unpaired
electron is 700 times larger than that of a proton, so the re-
sonance frequency/magnetic ﬁeld ratio for the electron is 28 GHz/
T, vs. 42.5 MHz/T for the proton. In principle, EPR is more sensitive
than NMR per net spin in the same magnetic ﬁeld. In practice,
however, the situation is different, especially in biological systems.
Namely, standard EPR spectrometers operate at much higher fre-
quencies and lower ﬁelds than conventional NMR spectrometers.
A standard commercial EPR spectrometer operates at 9.5 GHz (X-
band) - 0.34 T; while NMR spectrometers operate at frequencies
above 500 MHz, i.e. at magnetic ﬁelds above 10 T. Clinical MRI
machines operate at ﬁelds at/or above 1.5 T while small animal
imagers typically operate at 7 T or higher. The essential problem of
EPR experiments on small animals is the non-resonant absorption
of the electromagnetic radiation by the dielectric liquid water in
biological systems. At 9.5 GHz this effectively limits the sample
size to a thickness of a mouse tail. One could increase the pene-
tration depth of microwaves into larger aqueous samples by in-
creasing microwave power, but that would produce unacceptable
heating of the subject (a microwave oven). Hence, animals can be
studied only by reducing the operating frequency and corre-
sponding magnetic ﬁeld, but this results in reduced sensitivity.
Studies on small animals have been performed at the S-band (2–
3 GHz) with skin depth penetration, L-band (1.2 GHz) or even
lower (700 or 280 MHz) for whole body imaging. Another problem
is that commercial EPRI machines suitable for in vivo applications
were not available until recently, hence most of the researchers
used (and still are) a homemade apparatus or modiﬁcations of
commercial ones.
The most important difference between in vivo MRI and EPRI is
in the species that they detect. Both direct observations and the-
oretical calculations show that endogenous paramagnetic species
such as paramagnetic metal ions and free radicals are present in
insufﬁcient concentrations to be detected directly by EPR in vivo.
This presents an obvious problem since the paramagnetic sub-
stance has to be introduced in EPR experiments. On the other
hand, this has some beneﬁcial aspects, since the only para-
magnetic species that will be observed in vivo will be those in-
troduced by the experimenter. Also, the behavior of introduced
nitroxides can be related to metabolism. MRI sees water protons
which are abundant, enabling excellent images (water is 55 M and
nitroxides are usually injected at doses around 1 mmol/kg of body
weight). Nitroxides are seen indirectly through their effect on the
relaxation of water protons. EPRI does not provide images of
anatomy; it just shows the distribution of injected nitroxide within
the body and does not have very good spatial resolution. Con-
versely, MRI has excellent spatial resolution and provides detailed
anatomical information, but gives little information on the para-
magnetic species involved. Both techniques have their advantages
and drawbacks in in vivo ROS detection/imaging, thus the sensible
simultaneous use of both is a way to employ the optimal potential
of these techniques.
For example, it is possible to use both techniques in imaging
modality and overlay EPRI providing redox information on top of
MRI providing anatomical information [36,37]. There were also
constructions of dual EPR/MR imaging machines where both types
of information can be obtained without moving the animal
[30,38,39]. Probably the best way to fuse EPR and MRI into a single
machine is to use dynamic nuclear polarization (DNP or Over-
hauser effect, OMRI) which uses a unique method for detection of
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protons) in the magnetic ﬁeld is irradiated by RF at an EPR fre-
quency of nitroxides (unpaired electron), magnetization is trans-
ferred to protons enhancing water proton NMR signal intensities
and the overall effect is detected by conventional proton MRI. This
effect is completely different from classical enhancement of proton
relaxation by nitroxides (theoretically 330 times higher). Several
studies have demonstrated the efﬁciency of this technique in both
redox and oximetry studies [41–43]. It has been successfully de-
monstrated that OMRI machines accommodating large subjects
including humans can be built [41,44] opening possibilities of
combining all MRI capabilities with molecular speciﬁcity of EPR in
diagnosis and treatment follow up clinical studies. However, these
machines have to be homemade which is both technically de-
manding and expensive so only a few of them are in use. More
detail on the technical aspects of the combination of magnetic
resonance techniques can be found in recent reviews [45,46].
As emphasized before, the production of ROS species in vivo is
rather low and they are short-lived, hence their direct detection is
impracticable, if not impossible. Therefore, an addition of exo-
genous stable radicals such as nitroxides is needed to probe the
redox state in vivo. An alternative is to use spin-traps which con-
vert short-lived radicals (life-time shorter than milliseconds) into
more stable ones (life-time tens of minutes). In both approaches
there is a disruption of the natural redox system which raises the
question of toxicity. Intravenous (i.v.) injection of nitroxides at the
dose of up to 2 mmol/kg has been used to achieve reasonable
signal-to-noise (S/N) ratio for EPRI or EPRS, although much lower
doses have been used in the majority of studies. This is way be-
yond LD50 for nitroxides which is above 20 mmol/kg [47]. Transi-
tory changes in blood pressure or animal twitches may occasion-
ally occur especially when nitroxides with high cell penetrability
are used. The situation is different when spin traps are used. Spin
trapping is a very useful tool for studying a biochemical system in
vitro, with some potential for in vivo applications [48,49]. Naturally
occurring free radicals are scarce so a large amount of spin trap has
to be added (toxicity is an issue then), trapped radicals are short-
lived and have rather complicated EPR spectra which effectively
prevents the use of EPRI. Spin-traps can be used in vivo for iden-
tifying free radicals produced by some process or agent (e.g. ra-
diation), but are not very useful in pharmacokinetic studies.
There is a signiﬁcant difference in the data collection procedure
between EPRS and EPRI. A single ﬁeld scan of a few tens of seconds
is usually sufﬁcient for the line intensity of nitroxide spectra to be
measured (see Fig. 1A) and obtain a single time point. On the otherFig. 1. A. EPR spectrum of freely rotating nitroxide (TEMPONE #4) in an aqueous enviro
spectrum (dotted line) is 15N substituted and perdeuterated TEMPONE (15N PDT). B. EPRhand, to obtain an EPR image it is necessary to collect more than
10 spectra recorded at different directions of the magnetic ﬁeld
gradient, which can turn out to be a lengthy procedure.
Early in vivo EPRI were rather crude (same as ﬁrst MRI) and it
took some 5–6 min to make 2D images using ﬁltered back-pro-
jection with only 8 projections resulting in low spatial resolution
and poor time resolution for pharmacokinetic studies [16,21]. Yet,
at the same time the pharmacokinetics of nitroxides injected in
mice has been studied with EPRS with less than a minute time
resolution (Fig. 2A) [14]. It took a full 45 min to obtain a complete
3D data set [19], which certainly doesn’t allow any temporal stu-
dies. Nevertheless, such studies have stimulated further develop-
ment and today’s machines are capable of producing 3D EPR
images in around 1–2 min with up to 80 projections, where the
actual performance depends on a selected task [50,51]. However,
such machines are scarce and even such short imaging time may
not be sufﬁciently fast to follow the reduction of some nitroxides.
Hence the prudent choice of modality (EPRS or EPRI) is essential in
conducting a proper experiment since there is always a tradeoff
between spatial and temporal resolution. For example, it is rea-
sonable to select EPRI for the brain studies since various parts of
the brain or even different hemispheres might show a different
reduction kinetic. It does not make much sense to use EPRI for
studying e.g. the liver per se since it is unlikely that different liver
lobes will show any difference in reduction capacity. Whole body
imaging is justiﬁed if studying of multiple organs is attempted to
simultaneously analyze the biodistribution of nitroxides. The si-
tuation is of course different when tumors are implanted in var-
ious organs where imaging is necessary not only to differentiate
healthy tissue from tumors, but also to distinguish different zones
within the tumor itself (see Section 5 for details). No spectroscopy/
imaging dilemma is present when MR is used since nitroxides are
detected only indirectly through imaging. Most MRI machines are
capable of generating images with sufﬁcient anatomical resolution
in tens of seconds. However, such imaging sequences usually do
not have good sensitivity in detecting the effect of nitroxides.3. Biochemistry of nitroxides
Cyclic aminoxyl radicals with tetraalkyl substituents ﬂanking
the 4N–O functionality are most often used as probes for the
redox status in vivo, especially derivatives of TEMPO #1 or PROXYL
radicals #9 (Scheme 1). In contrast to nitroxide adducts derived
from nitrone spin traps, these probes persist almost indeﬁnitely innment. I – peak intensity, aN – hyperﬁne splitting, ΔHpp – line width. The inserted
spectrum of TEMPO #1 in the nonpolar (hydrocarbon) and polar (water) mixture.
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Scheme 1. Characteristic aminoxyl radicals used as probes of the redox status. These compounds are more frequently referred to as "nitroxides" or "nitroxyl radicals",
despite IUPAC recommendations. Most studies were conducted with derivatives of TEMPO 2,2,6,6-tetramethylpiperidine 1-oxyl (#1) and PROXYL 2,2,5,5-tetra-
methylpyrrolidine 1-oxyl (#9). Lipophilic doxyl stearates are incorporated into the membrane in cells with the doxyl moiety either close to the surface membrane in #17 or
deep in the membrane in #18 .
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position to the nitrogen and are dubbed as stable free radicals.
A typical spectrum of nitroxide is presented in Fig. 1A. All pi-
peridine or pyrrolidine nitroxides listed in Scheme 1 will have
almost identical spectra. Side groups do not contribute to the
overall appearance of the EPR spectrum, except through changes
of rotational time which may have an effect on the line width (Δ
Hpp). Multiple lines (line splitting) in EPR spectra originate from
the so-called hyperﬁne interaction of the unpaired electron spin
with the nuclear spin of 14N (I¼1) which according to the quan-
tum mechanical rule determines the number of lines (number of
lines ¼ 2Iþ1). A spectrum of 15N-PDT has only two lines since the
nuclear spin of 15N is I¼1/2. Perdeuteration removes super-hy-
perﬁne line broadening caused by interaction of the electron with
neighboring protons (nuclear spin of deuterium is one) and the
overall effect is that the line height of 15N-PDT is higher than in
natural nitroxides containing 14N resulting in a 5-fold increase of
the signal-to-noise ratio. The beneﬁts for EPRI are well understood
and explained [10] and 15N-PDT has been used in several studies
[52,53] but the wider use of 15N substituted and perdeuterated
nitroxides has been somewhat limited by their relatively high
price, which becomes an issue when in vivo experiments need to
be performed and relatively large amounts of nitroxides have to beinjected.
The hyperﬁne splitting of nitroxides depends on the polarity of
the solvent (Fig. 1B). In a nonpolar solvent the unpaired electron
delocalizes from the nitrogen atom, so the hyperﬁne coupling is
decreased when compared to the aqueous solution. This is an
important feature signifying that nitroxides can report on their
environment and a number of nitroxides reporting on micro-
polarity, microviscosity, local pH, temperature etc. have been de-
veloped. On the other hand, the amount of nitroxide in vivo is
always determined from the intensity of the low- and/or mid-ﬁeld
peak since the high-ﬁeld peak is not reliable for such measure-
ments. The doxyl stearate (DS) nitroxides are almost exclusively
located in phospholipid membranes, but their spectra are com-
plicated due to unresolved hyperﬁne splitting and are seldom used
in in vivo studies, but are very useful for studying biochemical
mechanisms in vitro.
These "stable" radicals can, however, participate in redox re-
actions with biological compounds or enzymes and thus report on
the redox status of the cell by shuttling between three forms
shown in Scheme 2). Since the position of the equilibrium reﬂects
the redox status, hydroxylamines or acyl-protected hydro-
xylamines, which are converted to hydroxylamines by esterases in
cells and tissues, can be used as alternative probes for oxidative
G. Bačić et al. / Redox Biology 8 (2016) 226–242230stress [54].
After incubation of a nitroxide radical with cells, a decay of the
EPR signal is observed, mainly due to the net reduction to hydro-
xylamine [55,56]. Many studies (mainly dating back to the 1970s
and 1980s) investigated the mechanisms underlying EPR signal
decay of nitroxides using various models or integrated systems and
the general principles of nitroxide metabolism are now well un-
derstood. Several mechanisms are involved, the relative importance
of which varies depending on the subcellular localization of the
nitroxide, hence on its lipophilicity and charge, and also on the
tissue of interest [57]. The rate of reduction of nitroxides by ascorbic
acid, a standard screening test for nitroxide stability, is mainly de-
pendent on the type of ring system [58–60]. Nitroxides based on a
six-membered piperidine ring are generally reduced faster than
analogues based on a ﬁve-membered pyrrolidine ring (Scheme 1).
The ﬂexibility of the piperidine ring, facilitating access of ascorbate
to the nitroxide, appears to be a better explanation for this effect
than the difference in redox potentials [60]. The presence of a
double bond in the ﬁve-membered structure slightly enhances
susceptibility to reduction. Ring substituents in each series further
inﬂuence the reaction rate, though to a lesser extent. Anionic
compounds (such as #3) are more stable than neutral compounds
(like #2 or #4), which in turn are more stable than cationic nitr-
oxides (such as amine #5 or tetraalkylammonium ion #6). This is
consistent with an electrostatic interaction between the nitroxide
and the monoanion ascorbate [58].
In functional biological systems, reduction of the nitroxides
occurs mainly within cells [24,61], so that the main structural
criterion governing the rate of reduction appears to be the ability
to enter cells. Charged compounds such as CAT-1 #6 or 3-CxP #11
are virtually incapable of crossing phospholipid membranes and
are fairly resistant to reduction [24]. Once within the cell, the rate
of reduction of the nitroxide is largely dependent on the ring size,
piperidine derivatives being reduced faster [24,61]. In cell sus-
pensions, the reduction process is mainly enzyme-dependent. It
may take place in mitochondria, especially mediated by ubiquinol
in the electron transport chain [62,63]. NAD(P)H-dependent sys-
tems in microsomal fractions can also be involved in the reduction
[59,64]. Alternatively, soluble enzymes of the hexose monopho-
sphate shunt can inﬂuence the reduction [65]. However, cytosol
demonstrates low reducing activity, except in cells containing
large amounts of ascorbate like hepatocytes and kidney cells
[64,66]. Thiols do not signiﬁcantly reduce the nitroxide radical in
vitro. However, they can indirectly contribute to its reduction in
biological systems by acting as secondary sources of reducing
equivalents [67]. Increased concentrations of oxygen within cells
usually lower the reduction rates by changing the redox states of
mitochondrial enzymes involved. The extent of this effect varies
depending on both the cell type and the lipophilicity of the nitr-
oxide [24,62,65,68,69]. The rate of reduction of lipophilic nitr-
oxides #17 and #18 in the doxyl stearate series is especially sen-
sitive to severe hypoxia (intracellular [O2]o1 μM) [62,68,69]. In
the presence of oxygen, oxidation back to the nitroxide of the lipid
soluble hydroxylamines occurs in membranes at the level of cy-
tochrome c oxidase and competes with the reduction of nitroxides
at a rate that increases with oxygen concentration [70]. In contrast,
water-soluble hydroxylamines are not signiﬁcantly oxidized by
cells [70].
In the context of oxidative stress, the nitroxide can be oxidized
to the oxoammonium cation by various oxidants such as the ferryl
heme species [71,72], ∙HO2 [73–75],
NO2, and ∙−CO3 [75–77] with
rate constants around 106–108 M1 s1. Direct reaction with the
hydroxyl radical does not seem to be signiﬁcant [78]. Instead,
nitroxides are known to detoxify HO-derived secondary radicals
such as protein-based and alkylperoxyl radicals [79,80]. These
reactions lead to an increased decay of the EPR signal compared tonormal tissues. The oxoammonium cation is a strong oxidant and
potentially harmful if it were to react with cellular components
[81,82]. However, it can be recycled to the nitroxide by a reaction
with ∙−O2 at diffusion-controlled rates, the nitroxide/ox-
oammonium pair acting as an SOD-mimic [73]. Alternatively, the
oxoammonium cation seems to be efﬁciently reduced to hydro-
xylamine by two-electron donors such as NAD(P)H or thiols [74].
The comproportionation reaction between the oxoammonium
cation and the hydroxylamine occurs at a negligible rate and does
not contribute to recycling of the nitroxide in cells [81]. Being an
efﬁcient chain-breaking antioxidant in the Fenton reaction, the
nitroxide also decays through its interaction with reduced transi-
tion metal ions (FeII, CuI), yielding the hydroxylamine [83]. The
latter can in turn be oxidized by a variety of reactive oxygen
species ( ∙−O2 , HO
, ONOO , H2O2 in the presence of transition
metal ions), the reaction with ∙−O2 being the primary non-enzy-
matic recycling pathway, though at a rate lower by several orders
of magnitude than the rate of the reaction of ∙−O2 with nitroxide
[78, 84].4. Analysis of pharmacokinetic curves
Previous Sections were devoted to various chemicals and ma-
chines needed to obtain the proper pharmacokinetical curve of
nitroxides. However, even having a perfect pharmacokinetic curve,
there are still obstacles before we can reach a conclusion on the
redox status (processes). Namely, the signal decay rate which
should reﬂect redox processes in the selected organ depends on,
beside the reduction of nitroxides, also on several kinetic factors
such as the distribution of the spin probe from the blood to the
tissue and within different tissue compartments, urinary excretion
through kidneys, fecal excretion through liver and bile, etc. To il-
lustrate the complexity of the problem, several examples of
pharmacokinetic curves for the two most studied organs (brain
and liver) and a few commonly used nitroxides are given in Fig. 2.
Fig. 2A presents the ﬁrst in vivo measurement of the pharma-
cokinetics of different nitroxides in the liver region obtained at the
L-band with a surface coil [14], which has been closely followed by
similar studies [15,17]. Different kinetics can be explained by the
difference in the structure of these nitroxides (see Section 2).
TEMPOL is a piperidine ring nitroxide (#2, Scheme 1) and the side
group enables its high cell membrane permeability. Hence, the fast
signal decay is to be expected mostly due to the whole body in-
tracellular reduction of TEMPOL to hydroxylamine. The CAT-1 is
also a piperidine ring nitroxide (#6), but its charge prevents per-
meation to cells and intracellular reduction. It appears that the
signal decay of CAT-1 is essentially due to kidney elimination since
there was a concomitant increase of CAT-1 in the bladder where it
was subsequently reduced by ascorbate present in urine. The
3-CxP is pyrrolidine nitroxide (#11) to which cell membranes are
reportedly impermeable just like for CAT-1, yet the difference in
the decay pattern is obvious. No attempts have been made to ex-
plain this bi-exponential behavior by authors, but the same signal
decay pattern has been found in a subsequent publication using
EPRS and 3-CxP [15,17], contrary to the data obtained using EPRI
[16,21,88], but the latter did not have a good time resolution to
properly assess the signal decay.
The research has been accelerated by synthesis of a new class of
nitroxides aimed primarily for brain studies. These blood-brain-bar-
rier (BBB) permeable nitroxides [89–92] improved brain research, but
also became very popular in studying other organs, especially BBB
and cell permeable 3-CP (#12) nitroxide. Fig. 2B and C show results
obtained for the pharmacokinetics of several nitroxides in liver and
brain compiled from various sources. The time course curves for the
decay of 3-CP in various studies differ, which is only to be expected –
Fig. 2. In vivo pharmacokinetics of nitroxides. A. Normalized decrease of the EPR signal intensities of nitroxides from the liver region of mice following the injection of three
different nitroxides at doses of 0.10 - 0.15 mmol/kg. Dotted lines denote the time of signal decrease to the half of the original value (half-time, t1/2). Inserted is an in vivo EPR
spectrum of 3-CxP, #11 (called PCA at the time) obtained 5 min after injection demonstrating an excellent signal/noise ratio (adapted from [14]). B. Compilation of phar-
macokinetic data for two nitroxides in the liver (tail vein injection). C. Compilation of pharmacokinetic data for three nitroxides in the brain (tail vein injection). D.
Compilation of pharmacokinetic data for three nitroxides in the liver and brain (i.m. or i.p. injection). Sources are given in brackets. Asterisks in C–D denotes some un-
published data from authors [85].
G. Bačić et al. / Redox Biology 8 (2016) 226–242 231different animals (rat or mice) on a different diet were used, different
doses of nitroxides, temperature control, ascorbate content, etc, but
they are not single exponential (decay after initial increase is what
reﬂects the redox state). We deliberately selected examples to de-
monstrate the point, but this behavior has been found in the majority
of studies, yet authors treated those, with a few exceptions [86,90], as
the pseudo-ﬁrst order kinetics deriving kinetic parameters from the
initial slope. The decay of TEMPOL and similar nitroxides appears to
be single-exponential in both liver and brain, the feature which has
been found in all studies. Nevertheless, it is difﬁcult to believe that a
nitroxide that readily distributes into various organs has such a
simple overall pharmacokinetics; we simply do not have sufﬁciently
fast machines to study it with adequate time resolution and sensi-
tivity to reveal the true pharmacokinetics.
Fig. 2A illustrates howmisleading treating all decay curves with
pseudo-ﬁrst order, i.e. with a single t1/2 can be. CAT-1 and 3-CxP
have the same t1/2 and very different overall pharmacokinetics.
Regardless of whether the decay curve appears to be single ex-
ponential, in vivo pharmacokinetics of nitroxides in organs cer-
tainly does not ﬁt to a single compartment model. The EPR signal
of nitroxides as measured in a certain organ is inevitably com-
posed of signals coming from the blood and that organ. Further,
tissues are composed of various compartments with a different
reducing capacity.Hence the primary goal in careful analysis of the pharmacoki-
netics of a certain nitroxide should be to distinguish the signal
decay arising from the reduction of a nitroxide within the organ
(extravascular/extracellular space and cells) from elimination
(washout) and/or reduction in the blood itself. To do that phar-
macokinetic models are needed for analysis of decay curves, which
then requires performing a multiparametric ﬁt. To verify the out-
come, it is necessary to have data from independent measure-
ments of certain kinetic parameters. Unfortunately, even mea-
surements of the reduction of nitroxides in blood in vivo proved
not to be an easy task. Numerous studies have been performed to
measure reduction of nitroxides in fresh blood in vitro or in the tail
(e.g. [22,27,93–96]). Data obtained from these measurements are
useful, but both approaches have serious ﬂaws. In vitro measure-
ments of reduction of nitroxide in blood give information on re-
ducing capacity of the blood itself (usually very low), but in an
in vivo experiment the blood nitroxide signal measured in a given
organ is actually reporting events from the whole body. Mea-
surements of nitroxide decay in the tail are hampered by the fact
that nitroxides can be distributed in tissues other than blood [22]
thus the measured decay is composed of processes in both tissues.
Measurements of the nitroxide concentration in the circulating
blood have been performed by a surgical procedure by which the
jugular vein was cannulated and blood was via tube circulated
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results, but is technically demanding. MRI measurements of the
pharmacokinetics of nitroxides in the blood in vivo have been
performed [28,98,99], but MRI is measuring nitroxides indirectly
and the procedure is not quantitative.
Another way to uncouple tissue reduction from the washout is
to use i.v. injection of KCl at the peak of the concentration-time
curve which produces almost immediate cardiac arrest [27], so
that the further signal decay is only due to nitroxide reduction
within the tissue. Also, a possibility of gaining insight into decay
mechanisms is to perform simultaneous studies on the same an-
imal model but using nitroxides with different characteristics (cell
permeability, resistance to reduction, lipophilicity). The approach
is illustrated in Fig. 2C where it is obvious that two nitroxides, 3-CP
and 3-CxP, have different decay kinetics due to different cell-per-
meability. Similar experiments have been performed in a rodent
brain [90,95] and tumor [98], but no pharmacokinetic models
were used to analyze results and assess the role of different
structures in the overall reduction decay. On the whole, there is no
study where all these possibilities have been employed together to
perform the detailed analysis of nitroxide pharmacokinetics.
Reduction of nitroxides when intramuscular (i.m.) or in-
traperitoneal (i.p.) injection is applied shows a completely differ-
ent situation (Fig. 2D). Now the dominant feature is the time for
nitroxides to reach the organ and not so the reduction kinetics
afterwards. Again the reduction of the TEMPOL signal is much
faster than for 3-CP, but it should be noted that the signal persisted
for almost an hour, unlike for i.v. injection, which is consistent
with similar previous studies [93,100]. Also, the study of hydro-
xylamine showed the same basic difference in pharmacokinetics
between the i.v. and i.p. injection [101]. These routes of adminis-
tration are not so useful for pharmacokinetic studies and are ra-
ther difﬁcult to model. Nevertheless, it is possible to obtain data onFig. 3. Penetration of DTBN (di-tert-butylnitroxide #19, a small non-cyclic nitroxide) into
of the distribution of DTBN obtained in the presence of a ﬁeld gradient orthogonal to skin
in different layers of the skin: top - epidermal surface; middle – epidermis; bottom – d
DTBN between apolar (h-1a) and polar (h-1p) microenvironments within the epidermiperfusion, oxygenation and tissue viability by combining in vivo
EPR and MRI and using the proper pharmacokinetic model. It is
somewhat puzzling that many authors just did not pay much at-
tention to the route of administration when discussing their re-
sults and comparing kinetic data from different administration
routes. Almost all examples given here are from i.v. injections of
nitroxides unless stated otherwise.5. Selected examples
The EPR and MRI techniques have been employed to map the
distribution of free radical metabolism in a variety of organs and
tissues. The list of examples and references given below is by no
means exhaustive; characteristic examples are selected to illus-
trate capabilities of these techniques to in vivo investigate the
redox status, focusing on the disease associated alterations of it.
5.1. Skin
The skin is an ideal target organ for EPRI for several reasons. It
is thin and detection of nitroxides applied topically does not re-
quire large penetration depth of microwaves so one can use the
S-band (2.2–3.0 MHz) for in vivo or even X-band for in vitro spe-
cimens, which results in an improved sensitivity. Imaging does not
require full 2D or 3D imaging; once nitroxides are applied topically
a simple spectral-spatial 1D imaging with one gradient orthogonal
to the skin surface is sufﬁcient to obtain distribution of nitroxides
and the redox status in the different skin layers. The surface loop
coils are sufﬁcient, i.e. the whole objects need not to be within the
resonator, which allows the EPRI of objects of any size, including
humans. This is an important feature since it opens the possibi-
lities of application of EPR in human (clinical) studies of not onlymouse skin as monitored by X-band EPRI. A, B, C Images of time dependent changes
surface: A – 5 min; B – 15 min; C – 45 min. D. EPR spectra of DTBN (2nd harmonics)
ermis. A splitting of the high ﬁeld line, h-1, into two peaks indicates distribution of
s and dermis. Adapted from [105].
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certain drugs, skin melanoma, oximetry [102–104].
A nice illustration of pharmacokinetics of nitroxides in skin as
studied by 1D spectral-spatial EPR is given in Fig. 3. Fuchs et al.
[105] studied diffusion of several nitroxides into skin biopsies of
hairless mice. By studying the spatially resolved diffusion of mal-
eimide-PROXYL (#15) nitroxide into different skin layers (surface,
epidermis, dermis), which chemically reacts with thiol groups,
they effectively determined the spatial distribution of thiol groups
as well. The analysis of spectral features showed spatially resolved
partitioning of the nitroxide di-tert-butylnitroxide (DTBN) #19
between polar and apolar regions (Fig. 3D, compare with Fig. 1B).
They also found that penetration of lipophilic nitroxides is much
faster than penetration of more hydrophilic nitroxides. They also
studied percutaneous absorption and distribution of a nitroxide-
labeled drug (estradiol) and a local anesthetic (procaine) ﬁnding
that the former readily penetrates into deep skin layers while the
latter does not, even in the presence of a penetration enhancer,
such as dimethylsulfoxide. This paper clearly demonstrated that
both the rate and spatial distribution of the physiological pro-
cesses involved in the metabolism of nitroxides or nitroxide-la-
beled compounds can be studied.
Although this research has been performed using X-band EPR
and skin biopsies, it set the stage for further extension for
in vivo applications, which always raises the question of toxicity.
Various nitroxide probes have been tested for biostability
in the skin and possible cutaneous irritation [106,107]. The
stability in skin biopsies, homogenates and cell cultures of kera-
tinocytes decrease in the following order imidazoline4
pyrrolidine4DTBN4piperidine4oxazolidine [106]. The irritation
potency of different nitroxides has been classiﬁed as nonirritant to
moderately irritant, thus, nitroxides can be safely employed for
in vivo EPR studies of skin even at high concentrations (100 mM)
[107].
The fact that some nitroxides and drugs are simply imperme-
able to skin, as demonstrated by studying their spin-labeled
equivalents, prompted another line of research of investigating
potential drug carriers. Group of authors [108,109] systematically
studied potential applications of liposomes as drug carriers for
topical treatment of skin disorders using 1D EPR. They found that
entrapment in liposomes promotes the penetration of otherwise
impenetrable charged nitroxides into skin and that the loss of
integrity of liposomes in different layers of the skin (indicating the
site of delivery) can be assessed. Studies revealed that the size and
phospholipid composition of liposomes signiﬁcantly inﬂuence
their efﬁciency, thus providing the base for their application inFig. 4. S-band, 2.2 GHz, EPR spectroscopy and imaging of 15N-PDT in phantom and skin
scanned in the absence (0 G/cm, dotted line) and presence (75 G/cm, solid line) of ﬁeld g
the presence of the ﬁeld gradient is due to the spatial separation of the two discs in the
show that a spatial resolution of 0.1 mm can be obtained. B. Color-coded image of the tim
function of skin depth. The decay kinetic has been ﬁtted to a single-exponential. Adapte
reader is referred to the web version of this article)medicine and cosmetics.
Nitroxide pharmacokinetics has been studied on various pre-
parations of skin homogenates and cell cultures [106,110], animal
[106,111,112] and human biopsies [106,113], as well as in vivo on
animal models [53,111,112,114] or on human subjects [111,115].
The principle for measuring distribution and pharmacokinetics is
the same as outlined in Fig. 3, except that measurements were
performed in vivo at lower frequencies and using more sophisti-
cated equipment (Fig. 4).
The larger part of research has been devoted to the evaluation
of the UV irradiation inﬂuence on the redox status of skin. UV ir-
radiation of the skin can cause inﬂammatory processes through
several possible mechanisms: (1) direct damage of DNA; (2) gen-
eration of different free radicals (ROS, lipid derived radicals –
peroxyl or alkyl), and (3) production of inﬂammatory agents
(prostaglandines, histamine). EPR studies are of importance for
two main reasons: (1) better understanding of processes under-
lying postulated oxidative damage induced by UV irradiation;
(2) examining free radical scavenging efﬁcacy of various anti-
oxidants and sunscreens for protection.
Enhanced production of ROS following UV irradiation of the
skin has been demonstrated by spin trapping [116,117] and also by
analyzing nitroxide decay kinetics [53,111–113,115]. In vivo mea-
surements of UVB inﬂuence on rat skin [53] and analysis of the
obtained 15N-PDT reduction kinetics showed the decrease of both
penetration and reduction rate in all skin layers after the exposure
to UVB light. The decrease of the reduction rate constants was
more pronounced in dermis and hypodermis than in epidermis
layer. Oximetry measurements showed that pO2 did not change
after treatment with UVB light, hence oxygen concentration and
microcirculation were disqualiﬁed as possible causes of alterations
in nitroxide reduction rates. Results of other authors [111–113],
however, showed the opposite trend – the increase of reduction
rate of nitroxide after the treatment of skin by UV light. Exposure
of the skin not only led to the change in nitroxide signal decay rate
constant, but also affected the shape of the kinetics curve (Fig. 5A)
[113]. Namely, when three different nitroxides (TEMPO, 3-CP and
3-CxP) were topically applied to nonirradiated skin biopsies, ki-
netics corresponded to ﬁrst order exponential process while upon
irradiation by UV light all the kinetics could be ﬁtted by bi-ex-
ponential function. It has been assumed that the faster process is
due to reduction of nitroxides by radicals produced by UV irra-
diation, while the slower process corresponds to reduction of
nitroxides by so called daughter radicals of ROS (for instance lipid
carbon centered and lipid peroxyl radicals). The work of Takeshita
et al. [112] adds to understanding of a probable causes of nitroxidein vivo. A. The low-ﬁeld peak of the nitroxide doublet in a layered disc phantom
radient applied normal to the surface of the disc phantom. The splitting observed in
phantom. 1D spatial image of disc phantom obtained from the projections. The data
e course of spatial distribution of 15N-PDT applied to a skin of human forearm as a
d from [115]. (For interpretation of the references to color in this ﬁgure legend, the
Fig. 5. Kinetics of nitroxide reduction and UV irradiation. A. Reduction of the nitroxides 3-CxP, 3-CP, and TEMPO applied to skin biopsies incubated in a 0.1 mM water/
ethanol solution of the nitroxide for 5 min. The reduction curves represent the signal loss without (open symbols) and with UV irradiation (closed symbols). Adapted from
[113]. B. Pharmacokinetics of nitroxide (3-CP) as measured with L-band EPR and surface coil placed on dorsal skin of a nude mice after i.v. injection of 3-CP [112]. Distinct
rapid and reversible changes in decay rate of 3-CP EPR signal in response to starting and stopping UVAþB illumination are clearly observable (a, b). The response of skin
surface temperature to the turning on and off of the UV light shows minor changes (c, d), which cannot affect nitroxide reduction.
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First, results clearly demonstrate that UV irradiation enhances
reduction of nitroxides (Fig. 5B). Preadministration of ROO sca-
vengers to the mice diminished rate of 3-CP signal decay in irra-
diated mice, whereas HO scavengers had no effect. None of the
previously mentioned scavengers affected 3-CP signal decay in
nonirradiated mice. Such ﬁnding indicated that faster loss of EPR
signal in skin exposed to UVAþB light occurred due to enhanced
ROS production, more speciﬁcally of ROO radicals.
5.2. Brain
The brain has been the subject of numerous ROS studies using
EPR/MRI. These include the studying of various conditions that can
induce oxidative stress and alter redox status such as ageing and
isolation, various induced diseases, hypoxia. Due to brain complex
structure most studies used an imaging mode often combining
EPR and MRI, which sometimes resulted in a low time resolution.
The role of ROS and antioxidants on ageing is the subject of
ongoing research and EPRS studies on young and old rodents re-
vealed that ageing diminishes the ability of the brain to reduce
injected nitroxides [20,86]. The study on intracerebral reducing
ability after acute stress in adult rats showed diminished reducingFig. 6. Reduction of nitroxides in ischemia reperfusion models. A. The decay kinetics of
30 min of reperfusion, after 1 h of MCAO [95]. B. Images of the brain 24 h after MCAO. T
half-life map shows the difference in nitroxide reduction. The selected regions of intereability in rats that were subjected to neonatal isolation [118].
Transient middle cerebral artery occlusion (MCAO) is a com-
mon method in studying ischemia/reperfusion (I/R) injuries. The
in vivo generation of ROS and its location in the brain were ana-
lyzed from the EPR signal decay data of three intra-arterially in-
jected spin probes with different membrane permeability (Fig. 6A).
The EPR signal decay of the probe with intermediate permeability
was signiﬁcantly enhanced 30 min after reperfusion following
MCAO, whereas no enhancement was observed with the other
probes. The antioxidant MCI-186 completely suppressed the en-
hanced in vivo signal decay after transient MCAO. These results
demonstrated that ROS generated during the initial stages of
transient MCAO cause brain injury. On the other hand, reduction
rates of MC-P (#13) were signiﬁcantly decreased 3h after re-
perfusion following transient MCAO [27]. A combination of 3D
EPRI and MRI has been used to map the half-lives of HM-P (#10) in
the mice brain 24h after MCAO [51]. Inhomogeneous half-lives
were clearly mapped pixel-by-pixel in the infarcted hemisphere
(Fig. 6B) and the average half-life of nitroxide was about 20%
longer when compared to the unaffected hemisphere. It has been
concluded that the difference arises from the different amount of
ascorbate in tissues.
A study of intracerebral reducing ability has been performed ondifferent spin probes (3-CxP, 3-CP, MC-P) administered intra-arterially to rats after
he MRI T2W image shows a massive lesion in the infarcted hemisphere, while the
st ROIs were used to calculate average reduction half-times [51].
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cephalopathy [119]. The ability of a mature rat brain to reduce BBB
permeable HM-P (#10) was depleted when compared to the
control; however this depletion was diminished by administering
an antioxidant agent after a hypoxic-ischemic insult.
Fig. 7 illustrates the basic concept of time resolved brain EPRI
[120]. Rats treated with kainic-acid (KA) induced seizure showed
that the hippocampal half-life of nitroxide MC-P (#13) after sei-
zures was signiﬁcantly prolonged indicating impaired reducing
ability, whereas the prolongation of the cortical half-life was not
signiﬁcant. The authors ascribed this difference to the different
amount of ascorbate in those tissues. These ﬁndings were con-
ﬁrmed by using an acyl-protected hydroxylamine which under-
goes intracellular oxidation to nitroxides [121] showing that oxi-
dative stress in the hippocampus and striatum in KA-treated ani-
mals is enhanced, but not in the cortex.
A common way of altering the redox state is to induce sepsis
using lipopolysaccharide (LPS). Fig. 8A shows that reduction of
HM-P in the brain of LPS treated mice is much faster than in the
control and images showed that the LPS-induced effect is homo-
geneous in all brain tissues [122]. The reduction rates were slower
than those in septic mice and became closer to the control when
aminoguanidine or allopurinol, which inhibit enzymatic activities
of induced nitric oxide synthase and xanthine oxidase, respec-
tively, were applied.
The reduction of nitroxide mito-TEMPO (#7, BBB- and cell-pe-
netrating) has been studied in the Parkinson’s disease animal
model (MPTP-treatment) in mice using MRI (Fig. 8B) [31]. The fast
reduction (t1/2 around 40 s) of mito-TEMPO has been recorded in
the dopaminergic area of the normal brain while in the MPTP
treated mice the mito-TEMPO enhanced MRI signal persisted
much longer (t1/2 around 20 min). Based on the redox cycle of
mito-TEMPO, the authors concluded that superoxide is a major
inducer and/or mediator of neurodegenerative damage in Parkin-
son’s disease.
A couple of studies performed on the effect of various neuro-
leptics, known to induce oxidative stress, on the brain redox status
revealed diminished ability of various brain areas in treated ani-
mals to reduce the injected nitroxide [123,124].
5.3. Other organs
Numerous model diseases and harmful conditions have beenFig. 7. EPRI of the rat brain in induced seizure. A. The dynamic pattern of selected transve
control groups at different times following injection of nitroxide MC-P (#13). B. Pharma
KA groups were 18.071.2 and 19.270.7 min, while the hippocampal half-lives of MC
Adapted from [120].studied using reduction of nitroxides. At the beginning measure-
ments were performed by placing surface coils over the selected
organ or inserting a certain part of the body into the loop coil. Ap-
plication of whole body EPRI was rare due to poor spatial resolution,
but this has changed with the development of EPR machines.
Nowadays, whole body imaging is more frequently performed using
some type of combining EPR with MRI (imaging fusion or hybrid
imagers, see Fig. 9) [30,36,37]. Numerous useful studies have been
performed on isolated perfused organs, particularly on the heart
[125], but here only in vivo studies will be reviewed.
Lungs have been studied mostly to determine the effect of
various toxins on their redox status [30,126–128]. An early EPR
study of nitroxide (administered intratracheally after euthanasia)
reduction in lungs revealed the well-known pattern that TEMPO
derivatives are reduced much faster than 3-CP, while 3-CxP was
almost not reduced at all [129]. An in vivo study on mice after
intratracheal instillation of diesel exhaust particles (DEP) showed
that such treatment signiﬁcantly enhances the decay rate of CAT-1
[127]. The enhancement was completely suppressed by the ad-
ministration of HO scavengers (catalase or desferrioxamine)
showing the direct evidence of HO generation by DEP. These
ﬁndings have been corroborated by another study where it was
found that reduction of CAT-1 in DEP mice and lung injury were
suppressed by a thiol protein thioredoxin-1 [128]. The reduction of
TEMPOL in lungs of asbestos exposed mice was signiﬁcantly de-
creased during the acute disease progression indicating changes in
the lung redox status in acute asbestosis [126]. It has been found
[30] that mice exposed to second hand smoking have a diminished
ability to reduce nitroxides not only in lungs but also in almost all
other organs (Fig. 9).
A number of studies have shown that oxidative stress is in-
creased in diabetes which via free radicals contributes signiﬁcantly
to the pathogenesis of diabetic angiopathy. Extensive research has
been performed by a Japanese group [87,130–133] using strepto-
zotocin-induced diabetes in rodents and reduction of 3-CP to
study source(s) of stress as well as agents that can be potentially
used in antioxidative therapy in diabetes. The reduction of nitr-
oxides in both liver and kidneys was faster in diabetes than in the
control in all studies. One of the main conclusions is that vascular
NAD(P)H is the principal contributor in diabetes induced oxidative
stress, which has been conﬁrmed by the ﬁndings that it is sup-
pressed by administering SOD, apocynin (NAD(P)H oxidase in-
hibitor), or statin.rsal EPR images of the rat head 5 mm posterior to the bregma in the KA-treated and
cokinetic curves for brain regions. The cortical half-lives of MC-P in the control and
-P in the control and KA groups were 10.470.8 and 15.970.7 min, respectively.
Fig. 8. The decay curves of nitroxides in brains of animals with induced diseases. A. Pharmacokinetics of a nitroxide HM-P (#10) in a control mouse and septic mouse head
obtained by in vivo EPRI [122]. Time course of the in vivo EPR signal intensity of HM-P in the control mouse and septic mice injected with LPS. (○) Control mouse head (t1/2
¼663 s); (◊) mouse injected with LPS only (t1/2¼374 s); mouse injected with LPS plus aminoguanidine (t1/2¼535 s) (■); mouse injected with LPS plus allopurinol (t1/2
¼489 s) (▲). B. Kinetic curves of the nitroxide-enhanced MRI signal in the brain of healthy (bottom line) and MPTP treated mice (top line) [31].
Fig. 9. Images and pharmacokinetics obtained on the hybrid co-imaging instrument, suitable for whole body imaging in both EPR and MR modalities without movement of
the animal. A. Whole body MRI image fromwhich transverse sections through selected organs were obtained. Renderings of the superimposed 3D EPRI and 3D proton MRI of
mice. The color map is for the EPR intensity (see color bar) of the 3-CP nitroxide probe distribution. Transverse slices through different organs of the animal showing the
temporal change of EPR intensity of 3-CP. The green contour depicts the ROI used to calculate the average EPR intensity distribution of the probe. B. Plot of the average signal
intensity values over time of the injected 3-CP as measured from the selected ROIs in control and smoke exposed animals. Adapted from [30]. (For interpretation of the
references to color in this ﬁgure legend,the reader is referred to the web version of this article).
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showed that CV159-Ca2þ/calmodulin blockade inhibiting Ca2þ
overloading has a profound effect on the liver reducing ability
[134]. Oxidative stress during ischemia-reperfusion acute renal
failure has been studied using EPRI and 3-CP [135]. Decay rates
were prolonged 3 days after I/R in both kidneys and liver. In liver
they recovered after 7 days, while recovery in kidneys was only
partial.
Low molecular weight iron complexes have been detected in
iron overload, which occurs in many diseases, and free radical
production through oxidative processes is suspected to be the
cause of iron toxicity. Free radical reactions have been studied by
EPR in an iron overload model [136]. The signal decay of 3-CP
detected in liver was signiﬁcantly enhanced in mice sub-
cutaneously loaded with ferric citrate (Fig. 10) and that enhance-
ment was suppressed by pre-treatment with either desferriox-
amine or the chain breaking antioxidant Trolox, but only slightly
suppressed by the hydroxyl radical scavenger DMSO.The redox status in hypertension (HT) has been studied in a
mice model by decay of the 3-CP signal in kidneys. Half-lives in HT
mice were signiﬁcantly higher than in control mice. This effect can
be reduced by application of the calcium channel blocker azelni-
dipine and was independent of blood pressure control [137]. Mice
that lack the Nrf2 transcription factor develop a lupus-like auto-
immune nephritis. Observed half-lives of 3-CP in the upper ab-
domen in Nrf2 mice, especially in aged ones, were signiﬁcantly
prolonged when compared to young and healthy ones [138].
Mucosal sulfhydryl compounds have been studied in experimental
colitis [139]. The decay rates of 3-CP were much slower in colitis
and agreed with the time dependent changes in mucosal glu-
tathione. The effect of X-radiation on the reduction of 3-CP in mice
liver has been studied to evaluate the potential of EPR in assessing
radiation induced oxidative stress [140]. The reduction rate has
been accelerated after irradiation, but suppressed by pre-
administration of the radioprotector cysteamine.
Fig. 10. EPR signal decay of 3-CP in the upper abdomen of mice in an iron overload
model. Note a departure of the decay curves from a single-exponential decay [136].
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It is well-known that the cancer cells and tissues have different
redox abilities from normal tissues. Differences in the redox status
between tumors and healthy tissue may originate from hypoxia
and increased concentrations of reducing agents in tumors.
It is essential to obtain good insight into the redox status of tumors
in order to design a proper therapy and estimate the response
of tumor to the therapy, since it is well-known that efﬁciency
of radiotherapy depends on oxygenation of tumors. For this
purpose reduction of different nitroxides has been studied by
in vivo EPR (both spectroscopy and imaging) and MRI on animal
models. Imaging is a preferable modality due to tumor tissue
heterogeneity.
The most studied tumors have been those implanted into the
thigh of rodents [28,98,141–144]. A series of studies performed
in vivo on radiation induced ﬁbrosarcoma (RIF-1) in mice [141–
143] generally showed that reduction of all cell-permeable nitr-
oxides (TEMPOL, 3-CP, HM-P) is faster in the tumor bearing legFig. 11. EPRI of the thigh of a mouse with an implanted RIF-1 tumor. A Selected EPR im
and frequency plot of 3-CP reduction rate constants calculated pixel-by-pixel assumin
nitroxide simultaneously measured in tumors and normal muscle of the contra lateral le
were collected simultaneously in the same animals. Adapted from [142].than in healthy muscle. Fig. 11A illustrates the heterogeneous ac-
cumulation of nitroxide in the tumor and heterogeneous dis-
tribution of reduction rates. It was also noticed that the amount of
nitroxide accumulated in healthy muscle was higher than in the
tumor bearing leg at the same time point after injection of the
probe. The lower concentrations and faster reduction of nitroxides
in the RIF-1 tumor were attributed to the higher concentrations of
GSH in the tumor bearing leg. Such a conclusion was supported by
the fact that animals treated with the glutathione synthesis in-
hibitor, buthionine sulphoximine (BSO), led to a substantial de-
crease in the reduction rate in the tumor (Fig. 11B).
The same authors also investigated the effect of oxygen on the
reduction rate of nitroxides. It has been found that the average
partial pressure of oxygen (pO2) in tumors was 3-fold lower than
in a normal tissue, which could contribute to the faster reduction
of nitroxides in tumors [141]. In tumor bearing mice which were
inhaling carbogen, the reduction rate of nitroxide at the tumor site
decreased when compared with the air-breathing mice [143]. The
signiﬁcantly decreased heterogeneity of redox maps and narrow
distribution of reduction rate constants on frequency plots of
carbogen breathing mice indicated that heterogeneity in the redox
status could be due to hypoxia and oxygen concentration hetero-
geneity in a tumor. However, experiments with simultaneous
measurements of the pO2 in tumors and the reduction rate at the
region of pO2 measurements showed rather poor correlation be-
tween these parameters, indicating that the extent of oxygenation
does not necessarily determine the redox status under air
breathing conditions [144].
Studies performed on squamous cell carcinoma (SCCVII), hu-
man colon carcinoma and KHT tumors using MRI to monitor the
reduction of nitroxides (TEMPOL and 3-CP) also showed faster
reduction in all tumor types (different reduction rates for different
types) than in normal muscle or other normal tissue [28,98]. Re-
duction in the muscle was the same in the tumor bearing and
contralateral leg [28]. Measurements of the total amount of nitr-
oxide either by MRI in vivo or by EPR on tissue homogenates
showed that the amount of nitroxides in tumors were similar to
those in muscles indicating that different reduction rates are the
result of different intracellular bioreduction. This conclusion has
been corroborated by the fact that there was no difference in the
rate of reduction of membrane impermeable 3-CxP between tu-
mor and muscle [98]. It has been suggested that tissue pO2 is not
the major determinant of the nitroxide reduction in vivo [28].
Studies performed on brain tumors (neuroblastoma and glio-
ma) by monitoring the reduction of cell- and BBB-permeable ni-
trosourea spin probe SLENU (#8) and TEMPOL by MRI alsoages of clearance of 3-CP nitroxide in tumors of untreated and BSO treated animals
g ﬁrst-order kinetics. B. The semilog plot showing the whole tissue clearance of
g. Images of tumor and muscle used for the measurement of pharmacokinetic data
Fig. 12. Nitroxide enhanced MRI images of healthy and tumor bearing mice in the early and terminal stage of disease [146]. Raw MRI images and extracted enhancement
images. MRI signal enhancement by nitroxide is clearly seen in the tumor at the terminal stage.
G. Bačić et al. / Redox Biology 8 (2016) 226–242238reﬂected the changed redox status of the tumor when compared
to the corresponding tissue of healthy animals [145, 146]. All brain
tissues (cancer and non-cancer) in cancer bearing animals were
characterized by a long half-life (t1/2414 min) indicating a high
oxidative activity, while brain tissues in healthy mice were char-
acterized by a short half-life (t1/2o3 min) [145]. This study has
been complemented by ﬁndings that the half-life of nitroxides in
the early stages of tumors is comparable to ones in healthy mice,
but much shorter than in tumors at terminal stages (Fig. 12). Such
behavior has been explained by the highly oxidizing activity of the
terminal-stage tumor, whereas an early-stage tumor is character-
ized by the reducing activity. The explanation was corroborated by
profound reoxidation of the injected hydroxylamine form of the
probe which occurred only in the terminal stage in tumor bearing
mice [146]. An interesting ﬁnding was the observation that the
redox potential of tissues distant from the primary tumor locus,
such as liver and lung, was altered in tumor bearing animals.
An entirely different approach in studying the redox status of
the tumor has been performed in a study aimed to measure in vivoglutathione in tumors [52]. Authors used the nitroxide probe
consisting of two nitroxide rings bound by the S-S bond which due
to the pairwise spin exchange of two radical subunits gives an EPR
spectrum different from the triplet pattern typical for mononitr-
oxide. Hence, it was possible to follow the reaction between the
probe and GSH by recording the increase of the monoradical EPR
spectrum from which kinetic parameters and the total amount of
GSH can be determined in vivo. One of the most important results
of this study is that the amount of intracellular GSH in cisplatin
resistant tumors is two times higher than in cisplatin sensitive
tumors, which is an important contribution towards a better un-
derstanding of the mechanisms of action of this widely used anti-
neoplastic agent.6. Conclusions and look to the future
EPR and MR imaging in vivo reached the level of a powerful tool
in experimental and preclinical studies of ROS/RNS or the redox
G. Bačić et al. / Redox Biology 8 (2016) 226–242 239status on animals. As evident from given examples, numerous stu-
dies performed previously only on in vitro or ex vivo samples have
been successfully transferred to in vivo conditions where basic con-
cepts and hypothesis can be tested under realistic conditions. Here
we reviewed only research related to some sort of pathologies but
the list of researches related to normal in vivo redox biochemistry/
physiology is more extensive. The success came from development of
more sensitive EPR machines and various EPR/MRI combinations (co-
registration, hybrid, OMRI) as well as from development of a host of
versatile nitroxide probes. The major problems appear to be the
expensiveness of machines and hence their scarcity, as well the lack
of coordination between centers where in vivo EPR/MRI studies on
redox mechanisms are performed.
Consequently, the basic concepts are well understood and
directions for future developments are pretty clear. On the in-
strumental side, further development of hybrid machines, espe-
cially OMRI, is an obvious way to go. This approach has been re-
cently extended, albeit in test tubes, to simultaneous imaging of
free radical intermediates involved in the mitochondrial electron
transport chain and radicals derived from vitamins E and K1 [147].
This opens a host of possibilities including metabolic imaging in
various pathologies and imaging of spin-trapped radicals. The
importance of such development lies in the possibility of ex-
tending such studies to humans and clinical research. OMRI ma-
chines combine almost all MRI capabilities with molecular speci-
ﬁcity of EPR which can be useful in diagnosis, but particularly
valuable in treatment follow-up studies. Instrumental develop-
ments have to be accompanied by developments of speciﬁc probes
suited for different purposes. Design of new probes with increased
stability towards reduction, enhanced sensitivity to oxidative
stress, or increased delivery into cells and through the blood–brain
barrier is needed and some good research has been recently
conducted in that direction [148–151]. Another line of improve-
ment is developing of probes which show speciﬁcity towards
certain ROS specie or speciﬁcity toward certain pathologies such as
tumors [152,153]. Due to the scarcity of centers possessing so-
phisticated equipment, a focused concerted effort on certain
cluster of widely relevant pathologies would certainly contribute
to the development of the ﬁeld. For example, studies of neuro-
degenerative disease (Parkinson, Alzheimer, Amyotrophic Lateral
Sclerosis, etc.), for whose development it is almost universally
agreed that ROS play a key role, would certainly propel these line
of researches towards clinical applications.Acknowledgment
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